Dinner S, Dunn TJ, Price E, et al. A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide, weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma. Int J Hematol. 2018, 108(3):267-273. doi: 10.1007/s12185-018-2468-5.

Articles

---

October 24th 2018

Study Summary: Amrubicin, Lenalidomide, and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Dinner S, Dunn TJ, Price E, et al. A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide, weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma. Int J Hematol. 2018, 108(3):267-273. doi: 10.1007/s12185-018-2468-5.

Latest Updated Articles

Published: November 15th 2024 | Updated: November 19th 2024

FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation

Published: April 1st 2024 | Updated: November 5th 2024

What We're Reading: Concierge Nonprofit Hospitals; Kaiser Permanente Elderly Care Program; Health Care Not Among Top Voter Issues

Published: October 21st 2024 | Updated: October 24th 2024

Lower Diagnostic Error Rates Found Among Hospitalized Patients During Care Transitions

Published: September 26th 2024 | Updated: October 1st 2024

Addressing Natural Disaster Takes Cooperation, Preparation to Ensure Patient Health

Published: May 9th 2024 | Updated: May 21st 2024

FDA Accepts Nivolumab Subcutaneous Injection Application, With Potential to Boost Access to PD-1 Inhibitors

Published: December 19th 2024 | Updated: December 26th 2024

The Dangerous Intersection of Breast Cancer and Cardiovascular Disease: A Call for Improved Prevention